Association Between IL-6 and Seizure Recurrence in Patients with the First Post-Ischemic Stroke Seizure
Authors Jia Q, Jiang F, Ma D, Li J, Wang F, Wang Z
Received 11 April 2020
Accepted for publication 13 July 2020
Published 11 August 2020 Volume 2020:16 Pages 1955—1963
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Dr Yuping Ning
Qi Jia,1 Fan Jiang,2 Daliang Ma,1 Jun Li,1 Fan Wang,1 Zhiqiang Wang1
1Encephalopathy Center, The Third People’s Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, People’s Republic of China; 2Neonatal Intensive Care Unit, The First People’s Hospital of Urumqi, Urumqi 830000, People’s Republic of China
Correspondence: Zhiqiang Wang
Encephalopathy Center, The Third People’s Hospital of Xinjiang Uygur Autonomous Region, No. 168, Nanchang Road, Urumqi 830000, People’s Republic of China
Tel/ Fax +86-9917530284
Purpose: To study the association between IL-6 level and seizure recurrence in patients with the first post-ischemic stroke seizure and assess its predictive value for seizure recurrence.
Patients and Methods: A total of 2976 consecutive ischemic stroke patients were retrospectively enrolled. Among them, 209 (7.02%) patients with the first post-ischemic stroke seizure were included in this analysis. The IL-6 mRNA expression level was evaluated through quantitative real-time PCR (qRT-PCR) and the 2−ΔΔCt method. Demographic data and clinical characteristics were collected. Univariate analysis was performed with independent-samples t-test, Mann–Whitney U-test, or chi-square test. Multivariate analysis was conducted using a backward stepwise logistic regression model for variables with P< 0.10 in univariate analysis. The predictive value was assessed using a receiver operating characteristic (ROC) curve.
Results: Among the patients included, 105 (50.24%) had recurrence of seizures, and 104 (49.76%) had no recurrence. Multivariate analysis demonstrated that the IL-6 mRNA expression level was independently correlated with seizure recurrence in patients with the first post-ischemic stroke seizure after adjusting for age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, cortical involvement, gender, electroencephalography (EEG) findings, and hemorrhagic transformation. When the IL-6 mRNA expression level was used to predict seizure recurrence, the area under the ROC curve (AUC) was 0.763 (SE=0.033, 95% CI=0.698– 0.829). The diagnostic power was moderate.
Conclusion: IL-6 was independently correlated with seizure recurrence in patients with the first post-ischemic stroke seizure and might be a potential biomarker for prediction of seizure recurrence.
Keywords: post-ischemic stroke seizure, seizure recurrence, IL-6, predictive value
Epilepsy is a complex, multifactorial neurological disease, which is mainly characterized by a predisposition to seizure recurrence.1 About 70 million people are affected by epilepsy all over the world, and one third of them are never free of seizures even when they receive a therapy employing anti-epileptic drugs.2 Ischemic stroke is an important cause of epilepsy, especially in elderly people.3 In the last decades, the incidence of post-stroke epilepsy has increased due to important advances in the therapeutic management of stroke that have reduced its mortality rate in the acute phase.4,5 A recent investigation reported that the incidence of post-stroke seizures could reach 15.3%.6 After stroke, epilepsy can threaten patients not only through potential physical injuries, but also through deleterious effects on the brain with stroke lesion and degenerative changes.7 In addition, recurrent peri-infarct depolarization may harm already vulnerable tissues through further neuronal injuries caused by the additional metabolic stress.8,9 Epilepsy after stroke has been demonstrated to be associated with decreased survival at 30-day and 1-year time points as well as increased length of hospital stay and resource utilization.10,12 The importance of post-stroke epilepsy also contemplates cognitive functioning, a lower disease-specific quality-of-life, and more disability and neurological impairment.13 Therefore, prediction and management of seizure recurrence is critical for stroke care. However, other studies did not observe any association between post-stroke seizures and long-term disability/mortality.14,15
Inflammation induced by the ischemic cerebrovascular process participates in the initiation and continuation of seizures.16,18 Interleukin-6 (IL-6) is a pro-inflammatory cytokine and associated with cardiovascular diseases,19,22 suggesting its critical role in the inflammatory response to cerebral ischemia.23 In addition, studies show that IL-6 is associated with development of seizures.24,26 Elevated IL-6 levels are confirmed in several different epilepsy etiologies and media.27 However, no previous studies investigated the association between IL-6 levels and seizure recurrence in patients with the first post-ischemic stroke seizure and its value in predicting seizure recurrence. In this study, we performed the above investigation with the aim of providing a basis for clinicians to predict seizure recurrence.
Patients and Methods
Between March 2013 and March 2018, 2976 consecutive ischemic stroke patients were retrospectively enrolled in the Third People’s Hospital of Xinjiang Uygur Autonomous Region. Among them, 209 (7.02%) patients were diagnosed with post-stroke seizure and included in this study. Data were obtained through reviewing medical records of their routine care for ischemic stroke and seizure at outpatient department visits and admission. Seizure recurrence was followed up by neurologists in all participants until March 2019. This study was conducted in accordance with the Declaration of Helsinki and received the approval of the ethics committee of the Third People’s Hospital of Xinjiang Uygur Autonomous Region (20130241018), and each participant provided written informed consent.
Inclusion and Exclusion Criteria of Included Patients
Inclusion criteria included 1) patients with first-ever ischemic stroke which was definitely diagnosed through signs and symptoms, magnetic resonance imaging (MRI), or computed tomography (CT) findings, and medical histories; 2) patients with the first post-ischemic stroke seizure which was determined based on the definition described by Fisher et al;28 3) complete medical records; and 4) informed consent. Exclusion criteria included 1) patients with potential epileptogenic lesions, such as cerebral vascular malformation, cerebral hemorrhage, brain tumor, traumatic brain injury, and cortical dysplasia; 2) patients with a family history of epilepsy or patients previously diagnosed with epilepsy; and 3) patients with transient ischemic attack (TIA).
Early onset was defined as the first post-ischemic stroke seizure occurring within 1 week after stroke insult and late onset as occurring outside 1 week. Seizure recurrence referred to the second unprovoked and separated seizure from the first one by >24 hours. Standard EEG of 20–30 minutes duration was conducted in all 209 patients within 24–72 hours of the first post-ischemic stroke seizure onset. Abnormal EEG findings included epileptiform discharge, generalized slow, and regional slow. Partial seizures were defined as originating within networks limited to one hemisphere, and generalized seizures were defined as originating at some point within, and quickly involving, bilaterally distributed networks.
Detection of the IL-6 mRNA Expression Level
The blood samples were collected after acute ischemic stroke (AIS) in all 209 patients. Total RNA was extracted from blood samples through the miRCURYTM RNA Isolation kit for Biofluids (Exiqon, Vedbaek, Denmark). cDNA was then synthesized with the miRCURY LNA Universal cDNA Synthesis Kit II (Exiqon, Vedbaek, Denmark). Quantitative Real-Time PCR (qRT-PCR) was performed with the Rotor-Gene® Q Real-Time Fluorescence Quantitative PCR Analyzer (Qiagen, Germany). The 2−ΔΔCt method was employed to assess the IL-6 mRNA expression level using GADPH as a reference gene. The primer sequences of IL-6 were 5ʹ-ATCAGGAGACCTGCTTGATG-3ʹ (sense) and 5ʹ-TGGTGGCTTTGTCTGGATTC-3ʹ (anti-sense), and the primer sequences of GADPH were 5ʹ-AGCCTCAAGATCAGCAATG-3ʹ (sense) and 5ʹ-CACGATACCAAAGTTGTCATGGAT-3ʹ (anti-sense).
All data were statistically analyzed through the SPSS version 19.0 for Windows (SPSS Inc., USA), and significance was set at P<0.05. Continuous data were validated for normality with Kolmogorov–Smirnov test. Normal data were demonstrated as mean±standard deviation (SD), and independent-samples t-test was used to perform univariate analysis; and non-normal data were demonstrated as median and interquartile range, and Mann–Whitney U-test was used to perform univariate analysis. Categorical data were demonstrated as ratios or percentages (%), and chi-square test was used to perform univariate analysis. Multivariate analysis was then conducted using a backward stepwise logistic regression model for variables with P<0.10 in univariate analysis. Among the variables included in multivariate analysis, age was a continuous variable, grades of the IL-6 mRNA expression level, NIHSS scores, and lesion size were multicategorical variables, and time of seizure, seizure type, cortical involvement, gender, EEG findings, and hemorrhagic transformation were binary variables. The predictive value was assessed using a receiver operating characteristic (ROC) curve.
Demographic Data and Clinical Characteristics
All 209 patients with the first post-ischemic stroke seizure included 117 (55.98%) males and 92 (44.02%) females. Their average age was 62.93±8.82 years, ranging from 37–82 years. Among them, 105 (50.24%) patients had recurrence of seizures (case group) and 104 (49.76%) patients had no recurrence (control group). The detailed demographic data and clinical characteristics are shown in Table 1. According to univariate analysis (Table 1), age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, and cortical involvement were statistically different between case group and control group (P<0.05), and the remaining variables were not statistically different (P>0.05).
Table 1 Demographic Data and Clinical Characteristics of Case Group and Control Group
IL-6 mRNA Expression Level
The average expression level of IL-6 mRNA was 4.87±1.91 for all 209 patients with the first post-ischemic stroke seizure, and the expression level was higher in the case group than in the control group (6.32±2.18 vs 3.41±1.64, t=10.912, P<0.001). The expression level were then classified into four grades according to the quartiles (Q1, Q2, and Q3) of the control group. Chi-square test also demonstrated that the expression level was higher in case group than in control group (Table 2).
Table 2 Number of Patients in Four Grades of the IL-6 mRNA Expression Level
Grades of the IL-6 mRNA expression level, age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, cortical involvement, gender, EEG findings, and hemorrhagic transformation were included in multivariate analysis. Multivariate analysis demonstrated that the IL-6 mRNA expression level was independently correlated with seizure recurrence in patients with the first post-ischemic stroke seizure after adjusting for age, NIHSS scores, time of seizure, seizure type, lesion size, location of the offending lesion to different hemispheric lobes, cortical involvement, gender, EEG findings, and hemorrhagic transformation (Table 3).
Table 3 Results of Multivariate Analysis
As shown in Figure 1, when grades of the IL-6 mRNA expression level was used to predict seizure recurrence in patients with the first post-ischemic stroke seizure, the area under the ROC curve (AUC) was 0.763 (SE=0.033, 95% CI=0.698–0.829), and the AUC adding IL-6 to the other independent variables associated with seizure recurrence was 0.820 (SE=0.029, 95% CI=0.762–0.877). When the IL-6 mRNA expression level >Q3 (5.27) was used as the diagnosis criterion, the diagnosis results are shown in Table 4. The AUC was 0.718 (SE=0.036, 95% CI=0.647–0.788). The sensitivity, specificity, accuracy, false positive rate, false negative rate, positive predictive value, and negative predictive value were 68.57%, 75.00%, 71.77%, 26.53%, 29.73%, 73.47%, and 70.27%, respectively. Therefore, its diagnostic power was moderate.
Table 4 Distribution Results of the IL-6 mRNA Expression Level >Q3 in the Case Group and Control Group
Figure 1 ROC curves of grades of the IL-6 mRNA expression level and adding IL-6 to the other independent variables in predicting seizure recurrence.
Inflammation after ischemic stroke is an unavoidable pathological process associated with post-ischemic injury in the brain.29,30 Peripheral and central inflammation can contribute to damage of the blood–brain barrier through upregulating inflammatory mediators. On the other hand, persistent inflammation can affect neuronal plasticity with network reorganization through several transcriptionally modulated mechanisms, which is potentially associated with aberrant and epileptogenic circuits.31,35 Seizures are well-acknowledged complications following ischemic stroke.36,37 Although their exact mechanism remains unknown, neurologic inflammation and damage to the blood–brain barrier are demonstrated indispensable components of epileptogenesis after brain injury.38 Several inflammatory cytokines, such as IL-6, IL-1β, etc., have been detected in human epileptogenic tissue and cerebrospinal fluid, and, meanwhile, they have also been shown as involvements in the initiation and continuation of seizures through experimental models.
IL-6 is a pro-inflammatory cytokine and its levels are low in the central nervous system under normal conditions. However, its levels elevate significantly in many diseases, for example, stroke, epilepsy, brain damage, and so on.39,40 During brain inflammation, IL-6 is primarily secreted by glial cells.41 Stimulation of microglia and astrocytes may result in increased secretion of IL-6.42 In addition, elevated levels of other inflammatory cytokines, such as IL-1β, IL-17, TNF-α, etc., can also upregulate the expression of IL-6.43 Fang et al44 demonstrated that IL-6 could inhibit neuronal necrosis and apoptosis through decreasing cytosolic Ca2+ overload induced by N-methyl D-aspartate, implying a neuroprotection of IL-6. However, Wang et al45 found that a chronic infusion of IL-6 could attenuate miniature excitatory postsynaptic currents regulated by N-methyl D-aspartate receptor in the hippocampal neurons of rats treated with anti-N-methyl D-aspartate receptor, which exacerbated memory impairment of rats. Therefore, IL-6 may bi-directionally impose influence on memory and synaptic plasticity.
Upregulated IL-6 levels can not only decrease hippocampal neurogenesis and long-term potentiation (LTP) but also increase gliosis and create conditions that may contribute to the onset of epilepsy.43,46 IL-6 can increase the blood–brain barrier permeability and has been shown as an association with development of seizures.24,26,47 Ho et al50 indicate that peripheral inflammation caused by lipopolysaccharide can increase seizure susceptibility through upregulating expression of IL-6, IL-1β, and TNF-α in the hippocampus. Erta et al43 found that transgenic IL-6 expression is pro-convulsive in mice. Samuelsson et al51 showed that prenatal exposure to IL-6 may lead to a higher risk of neurodegeneration of the hippocampus, inducing changes in both hippocampal morphology and structure. Pineda et al52 report that polyinosinic-polycytidylic acid can increase IL-6 in the offspring hippocampus through inducing maternal immune activation in experimental pregnancy, eventually resulting in faster progression of epileptogenesis and hippocampal hyperexcitability in the offspring.
In summary, IL-6 levels elevate significantly after stroke, and upregulation of IL-6 may contribute to the onset of epilepsy. In this study, the incidence of post-stroke seizures was 7.02%, which was basically consistent with the result of Fu et al53,54 (8.1%) and higher than Kim et al (3.3%). Multivariate analysis demonstrated that the IL-6 level was independently correlated with seizure recurrence in patients with the first post-ischemic stroke seizure after adjusting for NIHSS scores and lesion size. Therefore, IL-6 does not simply mediate the association between larger/more severe AIS and recurrent seizures. In addition to IL-6, the factors associated with seizure recurrence also included age, lesion size, cortical involvement, hemorrhagic transformation, and so forth. Higher age is a protective factor, which may be correlated with smaller cerebral cortex and decreased excitability induced by degenerative changes in elderly people.55 Cortical involvement is a recognized independent risk factor, especially the temporal and frontal lobe, which may be associated with dense cortical nerve cells with a lower threshold for seizures in this region.56 The extravasation and stimulation of blood metabolites may have epileptogenic effects in the acute phase of stroke,57 and so hemorrhagic transformation is a risk factor. Large lesions usually involve the temporal and frontal lobe.56 Therefore, large lesions are also associated with seizure recurrence.
We further assessed the value of IL-6 level in predicting seizure recurrence. The results showed that the diagnostic power was moderate with sensitivity of 68.57% and specificity of 75.00%. Therefore, IL-6 might be a potential biomarker for prediction of seizure recurrence. Kim et al54 developed a seizure recurrence risk score in the early post-stroke seizure after ischemic stroke patients. This score was based on atrial fibrillation, gender, functional disability, partial seizure type, and cortical lesion with sensitivity of 70.6% and specificity of 71.0%.
The main limitations of this study included 1) it was a retrospective analysis; 2) there was an unequivocal distribution of the follow-up period; and 3) other unknown variables, able to potentially influence the association between IL-6 and seizure recurrence, might have not been included in the analyses.
IL-6 level was independently associated with seizure recurrence in patients with the first post-ischemic stroke seizure. Therefore, IL-6 might be a potential biomarker for prediction of seizure recurrence.
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.
The authors report no conflicts of interest in this work.
1. Scheffer IE, Berkovic S, Capovilla G, et al. ILAE Classification of the Epilepsies: position Paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58(4):512–521. doi:10.1111/epi.13709
2. Ngugi AK, Bottomley C, Kleinschmidt I, et al. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883–890. doi:10.1111/j.1528-1167.2009.02481.x
3. Balami JS, Chen RL, Grunwald IQ, et al. Neurological complications of acute ischaemic stroke. Lancet Neurol. 2011;10(4):357–371. doi:10.1016/S1474-4422(10)70313-6
4. Hasan TF, Rabinstein AA, Middlebrooks EH, et al. Diagnosis and Management of Acute Ischemic Stroke. Mayo Clin Proc. 2018;93(4):523–538. doi:10.1016/j.mayocp.2018.02.013
5. Krueger H, Koot J, Hall RE, et al. Prevalence of Individuals Experiencing the Effects of Stroke in Canada: trends and Projections. Stroke. 2015;46(8):2226–2231. doi:10.1161/STROKEAHA.115.009616
6. Merkler AE, Gialdini G, Lerario MP, et al. Population-Based Assessment of the Long-Term Risk of Seizures in Survivors of Stroke. Stroke. 2018;49(6):1319–1324. doi:10.1161/STROKEAHA.117.020178
7. Zhao Y, Li X, Zhang K, et al. The Progress of Epilepsy After Stroke. Curr Neuropharmacol. 2018;16(1):71–78. doi:10.2174/1570159X15666170613083253
8. Karhunen H, Jolkkonen J, Sivenius J, et al. Epileptogenesis after experimental focal cerebral ischemia. Neurochem Res. 2005;30(12):1529–1542. doi:10.1007/s11064-005-8831-y
9. Back T, Ginsberg MD, Dietrich WD, et al. Induction of spreading depression in the ischemic hemisphere following experimental middle cerebral artery occlusion: effect on infarct morphology. J Cereb Blood Flow Metab. 1996;16(2):202–213. doi:10.1097/00004647-199603000-00004
10. Huang CW, Saposnik G, Fang J, et al. Influence of seizures on stroke outcomes: a large multicenter study. Neurology. 2014;82(9):768–776. doi:10.1212/WNL.0000000000000166
11. Burneo JG, Fang J, Saposnik G. Investigators of the Registry of the Canadian Stroke Network. Impact of seizures on morbidity and mortality after stroke: a Canadian multi-centre cohort study. Eur J Neurol. 2010;17(1):52–58. doi:10.1111/j.1468-1331.2009.02739.x
12. Arboix A, García-Eroles L, Massons JB, et al. Predictive factors of early seizures after acute cerebrovascular disease. Stroke. 1997;28(8):1590–1594. doi:10.1161/01.STR.28.8.1590
13. van Tuijl JH, van Raak EPM, van Oostenbrugge RJ, et al. Cognition and Quality of Life in Patients With Poststroke Epilepsy: A Case-Control Study. Epilepsy Behav. 2020;104(Pt B):106444. doi:10.1016/j.yebeh.2019.106444
14. Merlino G, Gigli GL, Bax F, et al. Seizures Do Not Affect Disability and Mortality Outcomes of Stroke: A Population-Based Study. J Clin Med. 2019;8(11):2006. doi:10.3390/jcm8112006
15. Phabphal K, Geater A, Limapichat K, et al. Risk Factors of Recurrent Seizure, Co-Morbidities, and Mortality in New Onset Seizure in Elderly. Seizure. 2013;22(7):577–580. doi:10.1016/j.seizure.2013.04.009
16. Lambertsen KL, Finsen B, Clausen BH. Post‑stroke inflammation-target or tool for therapy? Acta Neuropathol. 2019;137(5):693–714. doi:10.1007/s00401-018-1930-z
17. Wilson S. Task Force members. In response: indications and expectations for neuropsychological assessment in routine epilepsy care: report of the ILAE neuropsychology task force, diagnostic methods commission, 2013-2017. Epilepsia. 2015;56(8):1316–1317. doi:10.1111/epi.13055
18. Vitaliti G, Pavone P, Marino S, et al. Molecular Mechanism Involved in the Pathogenesis of Early-Onset Epileptic Encephalopathy. Front Mol Neurosci. 2019;12:118. doi:10.3389/fnmol.2019.00118
19. Hongmei Y, Yongping J, Jiyuan L. Interleukin-6 polymorphisms and risk of coronary artery diseases in a Chinese population: a case-control study. Pak J Med Sci. 2016;32(4):880–885. doi:10.12669/pjms.324.9908
20. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342(12):836–843. doi:10.1056/NEJM200003233421202
21. Ridker PM, Rifai N, Stampfer MJ, et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101(15):1767–1772. doi:10.1161/01.CIR.101.15.1767
22. Castillo J, Rodríguez I. Biochemical changes and inflammatory response as markers for brain ischaemia: molecular markers of diagnostic utility and prognosis in human clinical practice. Cerebrovasc Dis. 2004;17(Suppl 1):7–18. doi:10.1159/000074791
23. Beamer NB, Coull BM, Clark WM, et al. Interleukin-6 and interleukin-1 receptor antagonist in acute stroke. Ann Neurol. 1995;37(6):800–805. doi:10.1002/ana.410370614
24. Taalab M, Mohammed WF, Helmy MA, et al. Cannabis Influences the Putative Cytokines-Related Pathway of Epilepsy among Egyptian Epileptic Patients. Brain Sci. 2019;9(12):
25. Uludag IF, Duksal T, Tiftikcioglu BI, et al. IL-1β, IL-6 and IL1Ra levels in temporal lobe epilepsy. Seizure. 2015;26:22–25. doi:10.1016/j.seizure.2015.01.009
26. Alapirtti T, Lehtimäki K, Nieminen R, et al. The production of IL-6 in acute epileptic seizure: A video-EEG study. J Neuroimmunol. 2018;316:50–55. doi:10.1016/j.jneuroim.2017.12.008
27. de Vries EE, van den Munckhof B, Braun KP, et al. Inflammatory mediators in human epilepsy: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2016;63:177–190. doi:10.1016/j.neubiorev.2016.02.007
28. Fisher RS, Acevedo C, Arzimanoglou A, et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475–482. doi:10.1111/epi.12550
29. Chamorro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke. 2006;37(2):291–293. doi:10.1161/01.STR.0000200561.69611.f8
30. McColl BW, Allan SM, Rothwell NJ. Systemic infection, inflammation and acute ischemic stroke. Neuroscience. 2009;158(3):1049–1061. doi:10.1016/j.neuroscience.2008.08.019
31. Pugazhenthi S, Zhang Y, Bouchard R, et al. Induction of an inflammatory loop by interleukin-1beta and tumor necrosis factor-alpha involves NF-kB and STAT-1 in differentiated human neuroprogenitor cells. PLoS One. 2013;8(7):e69585. doi:10.1371/journal.pone.0069585
32. Ross FM, Allan SM, Rothwell NJ, et al. A dual role for interleukin-1 in LTP in mouse hippocampal slices. J Neuroimmunol. 2003;144(1–2):61–67. doi:10.1016/j.jneuroim.2003.08.030
33. Del Rey A, Balschun D, Wetzel W, et al. A cytokine network involving brain-borne IL-1beta, IL-1ra, IL-18, IL-6, and TNFalpha operates during long-term potentiation and learning. Brain Behav Immun. 2013;33:15–23. doi:10.1016/j.bbi.2013.05.011
34. Yin P, Li Z, Wang YY, et al. Neonatal immune challenge exacerbates seizure-induced hippocampus-dependent memory impairment in adult rats. Epilepsy Behav. 2013;27(1):9–17. doi:10.1016/j.yebeh.2012.12.015
35. Balosso S, Maroso M, Sanchez-Alavez M, et al. A novel non-transcriptional pathway mediates the proconvulsive effects of interleukin-1beta. Brain. 2008;131(Pt 12):3256–3265. doi:10.1093/brain/awn271
36. Menon B, Shorvon SD. Ischaemic stroke in adults and epilepsy. Epilepsy Res. 2009;87(1):1–11. doi:10.1016/j.eplepsyres.2009.08.007
37. George P, Punia V, Natteru PA, et al. Predictors of Seizure Recurrence after Acute Symptomatic Seizures in Ischemic Stroke Patients. Neurosci J. 2019;2019:8183921. doi:10.1155/2019/8183921
38. Choi J, Koh S. Role of brain inflammation in epileptogenesis. Yonsei Med J. 2008;49(1):1–18. doi:10.3349/ymj.2008.49.1.1
39. Pera J, Zawadzka M, Kaminska B, et al. Influence of chemical and ischemic preconditioning on cytokine expression after focal brain ischemia. J Neurosci Res. 2004;78(1):132–140. doi:10.1002/jnr.20232
40. Yamashita T, Sawamoto K, Suzuki S, et al. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem. 2005;94(2):459–468. doi:10.1111/j.1471-4159.2005.03227.x
41. Alyu F, Dikmen M. Inflammatory aspects of epileptogenesis: contribution of molecular inflammatory mechanisms. Acta Neuropsychiatr. 2017;29(1):1–16. doi:10.1017/neu.2016.47
42. Gruol DL.IL-6 regulation of synaptic function in the CNS. Neuropharmacology. 2015;96(Pt A):42–54. doi:10.1016/j.neuropharm.2014.10.023
43. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254–1266. doi:10.7150/ijbs.4679
44. Fang XX, Jiang XL, Han XH, et al. Neuroprotection of interleukin-6 against NMDA-induced neurotoxicity is mediated by JAK/STAT3, MAPK/ ERK, and PI3K/AKT signaling pathways. Cell Mol Neurobiol. 2013;33(2):241–251. doi:10.1007/s10571-012-9891-6
45. Wang X, Ma C, Liu CY, et al. Neuronal NMDAR Currents of the Hippocampus and Learning Performance in Autoimmune Anti-NMDAR Encephalitis and Involvement of TNF-α and IL-6. Front Neurol. 2019;10:684. doi:10.3389/fneur.2019.00684
46. Levin SG, Godukhin OV. Modulating effect of cytokines on mechanisms of synaptic plasticity in the brain. Biochemistry (Mosc). 2017;82(3):264–274. doi:10.1134/S000629791703004X
47. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280–4288. doi:10.3748/wjg.14.4280
48. Yarlagadda A, Alfson E, Clayton AH. The blood brain barrier and the role of cytokines in neuropsychiatry. Psychiatry. 2009;6(11):18–22.
49. Vezzani A, French J, Bartfai T, et al. The role of inflammation in epilepsy. Nat Rev Neurol. 2011;7(1):31–40. doi:10.1038/nrneurol.2010.178
50. Ho YH, Lin YT, Wu CW, et al. Peripheral inflammation increases seizure susceptibility via the induction of neuroinflammation and oxidative stress in the hippocampus. J Biomed Sci. 2015;22:46. doi:10.1186/s12929-015-0157-8
51. Samuelsson A, Jennische E, Hansson H, et al. PrenAtAl exposure to interleukin-6 results in inflAmmAtory neurodegenerAtion in hippocAmpus with NMDA </sub>/GABA A dysregulAtion And impAired spAtiAl leArning. Am J Physiol Regul Integr Comp Physiol. 2005;290(5):R1345–1356. doi:10.1152/ajpregu.00268.2005
52. Pineda E, Shin D, You SJ, et al. Maternal immune activation promotes hippocampal kindling epileptogenesis in mice. Ann Neurol. 2013;74(1):11–19. doi:10.1002/ana.23898
53. Fu MM, Wang YZ, Li YK, et al. Recurrence after the first epileptic seizure in patients with stroke: an analysis of risk factors. Chin J Cerebrovasc Dis. 2018;15(8):398–403.
54. Kim HJ, Park KD, Choi KG, et al. Clinical Predictors of Seizure Recurrence After the First Post-Ischemic Stroke Seizure. BMC Neurol. 2016;16(1):212. doi:10.1186/s12883-016-0729-6
55. Petrides G, Braga RJ, Fink M, et al. Seizure threshold in a large sample: implications for stimulus dosing strategies in bilateral electroconvulsive therapy: a report from CORE. J ECT. 2009;25(4):232–237. doi:10.1097/YCT.0b013e31819c76ff
56. Tanaka T, Yamagami H, Ihara M, et al. Seizure outcomes and predictors of recurrent post-stroke seizure: a retrospective observational cohort study. PLoS One. 2015;10(8):e0136200. doi:10.1371/journal.pone.0136200
57. Chen TC, Chen YY, Cheng PY, et al. The incidence rate of post-stroke epilepsy: a 5-year follow-up study in Taiwan. Epilepsy Res. 2012;102(3):188–194. doi:10.1016/j.eplepsyres.2012.06.003
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]